Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind placebo-controlled SAD study of SCO-240 in healthy adults
jRCT2051210027Phase 1Not yet recruiting
- Sponsor
- SCOHIA PHARMA, Inc.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SCO-240 in cholelithiasis (9 arms), sponsored by SCOHIA PHARMA, Inc. Primary endpoints: Safety and tolerability of single oral doses of SCO-240, Pharmacokinetics of SCO-240 and 1 more. Planned start May 2021; status: not yet recruiting.
02
Drugs
SCO-240
03
Conditions
cholelithiasis
Beyond the preview
Go deeper on jRCT2051210027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210027.